crolibulin and Neoplasms

crolibulin has been researched along with Neoplasms* in 1 studies

*Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. [MeSH]

Trials

1 trial(s) available for crolibulin and Neoplasms

Article	Year
Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin. Scientific reports, 2020, 09-02, Volume: 10, Issue:1 The vascular disrupting agent crolibulin binds to the colchicine binding site and produces anti-vascular and apoptotic effects. In a multisite phase 1 clinical study of crolibulin (NCT00423410), we measured treatment-induced changes in tumor perfusion and water diffusivity (ADC) using dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DW-MRI), and computed correlates of crolibulin pharmacokinetics. 11 subjects with advanced solid tumors were imaged by MRI at baseline and 2-3 days post-crolibulin (13-24 mg/m Topics: Adult; Aged; Benzopyrans; Blood Vessels; Contrast Media; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Female; Gadolinium; Humans; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic	2020

Article

Year

Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin.

Scientific reports, 2020, 09-02, Volume: 10, Issue:1

The vascular disrupting agent crolibulin binds to the colchicine binding site and produces anti-vascular and apoptotic effects. In a multisite phase 1 clinical study of crolibulin (NCT00423410), we measured treatment-induced changes in tumor perfusion and water diffusivity (ADC) using dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DW-MRI), and computed correlates of crolibulin pharmacokinetics. 11 subjects with advanced solid tumors were imaged by MRI at baseline and 2-3 days post-crolibulin (13-24 mg/m

Topics: Adult; Aged; Benzopyrans; Blood Vessels; Contrast Media; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Female; Gadolinium; Humans; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic

2020